c-MYC-regulated miR-23a/24-2/27a Cluster Promotes Mammary Carcinoma Cell Invasion and Hepatic Metastasis by Targeting Sprouty2
Year: 2013
Type: article
Abstract: Emerging evidence indicates that the miR-23a / 24-2 / 27a cluster may possess a causal role in mammary tumorigenesis and function as a novel class of oncogenes. However, the regulatory mechanism of the miR-23a / 24-2 / 27a cluster in mammary carcinoma cell invasion and migration is still largely unknown. We observed that the expression levels of miR-23a , miR-24-2 and miR-27a were significantly higher in breast cancer with lymph node metastasis, compared with that from patients without lymph node metastasis or normal tissue. Forced expression of the miR-23a / 24-2 / 27a cluster promoted mammary carcinoma cell migration, invasion, and hepatic metastasis, through targeting Sprouty2 ( SPRY2 ) and consequent activation of p44/42 MAPK. Epidermal growth factor induced the expression of the transcription factor c-MYC, which promoted the expression of mature miR-23a , miR-24-2 , and miR-27a and subsequently decreased expression of SPRY2 and activated p44/42 MAPK to promote mammary carcinoma cell migration and invasion. We therefore suggest a novel link between epidermal growth factor and the miR-23a / 24-2 / 27a cluster via the regulation of c-MYC, providing the potential for the miR-23a / 24-2 / 27a cluster to be used as biomarker in the diagnosis and/or treatment of breast cancer. Background: The regulation of the miR-23a / 24-2 / 27a cluster is largely unknown. Results: EGF induced c-MYC expression to promote the expression of the miR-23a / 24-2 / 27a cluster, resulting in decreased expression of Sprouty2 and increased activation of p44/42 MAPK to stimulate mammary carcinoma cell invasion and subsequent hepatic metastases. Conclusion: EGF promoted mammary carcinoma cell invasion and hepatic metastasis. Significance: The miR-23a / 24-2 / 27a cluster might be used as a biomarker for breast cancer metastasis.
Source: Journal of Biological Chemistry
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,430
OpenAlex ID: W1984000435
